Myeloproliferative neoplasms trials in United States

In United States 116 Also abroad 210

116 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Where
New York, Westwood, Winston-Salem
Age
18 years and over
People
26
Run by
John Mascarenhas
See details and how to joinNCT07447817
Phase 1Taking people
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Where
Ann Arbor, Atlanta, Babylon, Baltimore, Birmingham, Boston, Charlotte, Columbus, Duarte, Durham, Eugene, Gilbert, Houston, Irvine, Kansas City, Nashville, New York, Richmond, Salt Lake City, Seattle, St Louis, Tampa, Winston-Salem
Age
18 years and over
People
250 worldwide
Run by
Damora Therapeutics
See details and how to joinNCT07849231
Phase 2Taking people
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Where
Seattle
Age
6 months to 65 years
People
54
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT06013423
Phase 1/2Taking people
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
Where
Orange
Age
18 years and over
People
10
Run by
University of California, Irvine
See details and how to joinNCT07281781
Phase 2Taking people
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Where
Atlanta, Boston, Duarte
Age
18 years to 75 years
People
216
Run by
City of Hope Medical Center
See details and how to joinNCT06059391
Phase 1Taking people
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Where
Atlanta, Boston, Duarte
Age
18 years to 75 years
People
46
Run by
City of Hope Medical Center
See details and how to joinNCT07020533
Phase 1/2Taking people
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Where
Ann Arbor, Atlanta, Aurora, Canton, Cleveland, Columbus, Duarte, East Brunswick, Gettysburg, Gilbert, Houston, Iowa City, Irvine, Jacksonville, Los Angeles, Maumee, Miami, Milwaukee, New York, Philadelphia, Portland, Rochester, Rolling Meadows, San Francisco, Seattle, St Louis, Tampa, Temple, Winston-Salem
Age
18 years and over
People
150 worldwide
Run by
Disc Medicine, Inc
See details and how to joinNCT05320198
Phase 1Taking people
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Where
Houston, New York, Sacramento, The Bronx
Age
18 years and over
People
24
Run by
Cellenkos, Inc.
See details and how to joinNCT05423691
Phase 1Taking people
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Where
Denver, Houston, Nashville, Sacramento, Seattle
Age
18 years to 85 years
People
18
Run by
CERo Therapeutics Holdings, Inc.
See details and how to joinNCT06834282
Phase 1Taking people
Therapeutic RSK1 Targeting in Myeloid Malignancies
Where
St Louis
Age
18 years and over
People
30
Run by
Washington University School of Medicine
See details and how to joinNCT07379125
Phase 1Not yet taking people in United States
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
Where
Buffalo
Age
18 years and over
People
20
Run by
Roswell Park Cancer Institute
See details and how to joinNCT07679334
No phaseTaking people
Pacritinib Effectiveness in Real-world Settings
Where
Charleston, Columbus, Nashville, New Haven, Tampa
Age
18 years and over
People
60
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT07774455
Phase 2Taking people
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Where
Pittsburgh, Seattle, Tampa
Age
1 year to 60 years
People
120
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT03970096
No phaseTaking people
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Where
Cleveland
Age
Up to 30 years
People
20
Run by
Case Comprehensive Cancer Center
See details and how to joinNCT06421155
Phase 2Taking people
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Where
Seattle
Age
18 years to 75 years
People
50
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT07228624
Phase 1Taking people
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
Where
Salt Lake City
Age
18 years and over
People
15
Run by
University of Utah
See details and how to joinNCT07521046
No phaseTaking people
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Where
Chicago, Miami, San Antonio
Age
18 years and over
People
400
Run by
University of Miami
See details and how to joinNCT05745285
Phase 2Not yet taking people in United States
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Where
New York
Age
18 years and over
People
20
Run by
John Mascarenhas
See details and how to joinNCT07872709
Phase 2Not yet taking people in United States
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Where
Milwaukee
Age
18 years and over
People
450
Run by
Medical College of Wisconsin
See details and how to joinNCT07572929
Phase 2Taking people
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Where
Birmingham
Age
18 years to 60 years
People
29
Run by
University of Alabama at Birmingham
See details and how to joinNCT06315309
Phase 1Taking people
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Where
Ann Arbor, Boston, Charlotte, Cincinnati, Columbus, Houston, Kansas City, New York, Palo Alto, St Louis, Tampa
Age
18 years and over
People
256 worldwide
Run by
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00
Phase 1/2Taking people
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Where
Houston
Age
18 years and over
People
66
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT07128381
Phase 1/2Taking people
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Where
Houston
Age
18 years and over
People
97
Run by
M.D. Anderson Cancer Center
See details and how to joinNCT04140487
Early phase 1Taking people
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Where
Baltimore
Age
18 years and over
People
8
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
See details and how to joinNCT06398457
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Ann Arbor, Atlanta, Baltimore, Birmingham, Boston, Buffalo, Charleston, Charlottesville, Chicago, Columbus, Denver, Duarte, Durham, Gainesville, Hackensack, Houston, Los Angeles, Miami, Minneapolis, Nashville, New Haven, Newport Beach, New York, Salt Lake City, Seattle, St Louis, The Bronx, Tucson
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00